What the 10 drugs subject to Medicare price negotiations currently cost

President Biden announced Tuesday the 10 medications that his administration will include in the next drug price negotiation for those covered under Medicare Part D.

The drugs are Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp, the White House said — adding that the price negotiations are the first move in a new effort to lower the costs of dozens of other drugs over the next couple of years.

The White House provided the average price of the drugs, including:

• Eliquis, used for the prevention and treatment of blood clots, has an average part D-covered prescription drug cost per enrollee of $4,448.
• Jardiance is used in the treatment of diabetes or heart failure, which costs enrollees on average $4,487.
• Xarelto, used to prevent and treat blood clots and reduce risk for patients with coronary or peripheral artery disease, costs $4,511 per enrollee.
• Januvia and Farxiga, used to treat diabetes, cost enrollees, on average, $4,703 and $4,091, respectively. Farxiga is also used in treatments for heart failure and chronic kidney disease.
• Entresto, used to treat heart failure, costs Medicare Part D recipients $4,915, on average, the White House said.
• Enbrel and Stelara, used to treat psoriasis and psoriatic arthritis, cost Medicare recipients $58,148 and $119,951 per enrollee, respectively. Enbrel is also used as a Rheumatoid arthritis medication, while Stelara is used to treat Crohn’s disease and ulcerative colitis.
• Imbruvica, used in treatment for various blood cancers, comes with a steep price tag of $133,178 per enrollee.
• Other diabetes-related products, including Fiasp, Fiasp FlexTouch and the Fiasp PenFill as well as NovoLog, NovoLog FlexPen and the NovoLog PenFill cost on average $3,316 per Medicare enrollee.

"No senior should have to overpay for life-saving drugs to pad Big Pharma’s pockets," Biden said on X, formerly known as Twitter. "My Administration is announcing the first 10 Medicare Part D drugs selected for price negotiation."

HOUSE PASSES BILL CAPPING INSULIN AT $35 A MONTH FOR PATIENTS WITH INSURANCE

He added, "We're ending the days of deciding between buying your medicine or putting food on the table."

In the announcement, the White House said the 10 drugs are "among those with highest total spending in Medicare Part D," as they are used to help treat diabetes, heart failure, psoriasis, blood cancers, Crohn’s disease and other health conditions.

"Today, the Biden-Harris Administration is delivering on another significant milestone in implementing President Biden’s historic law to lower health care and prescription drug costs and ushering in a new era for American seniors. Over the next 4 years, Medicare will negotiate prices for up to 60 drugs covered under Medicare Part D and Part B, and up to an additional 20 drugs every year after that," the announcement added.

NOVO NORDISK TO LOWER INSULIN PRICES BY 75%

"Millions of Part D enrollees depend on these vital treatments to treat life-threatening conditions including diabetes, heart failure, and cancer, but many struggle to access their medications because of prohibitive costs," the White House continued.

"Medicare drug price negotiation will result in lower out-of-pocket costs for seniors and will save money for American taxpayers," the White House added. "Negotiations for the first group of selected drugs will begin in 2023, with negotiated prices going into effect in 2026."

WHAT IS MEDICARE, AND HOW DO YOU GET IT?

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The cost reduction comes as the Biden administration previously capped insulin costs at $35 per month for seniors and others on Medicare with diabetes.